High Growth Tech In Asia Featuring Three Prominent Stocks

Simply Wall St

Tue, December 9, 2025 at 11:38 PM EST 4 min read

As global markets experience fluctuations with hopes for interest rate adjustments, the technology sector in Asia continues to capture significant attention, particularly as Chinese stock markets show enthusiasm for domestic tech and AI despite broader economic challenges. In this context, identifying strong stocks often involves looking at companies that demonstrate resilience and innovation in rapidly evolving sectors, which can be crucial amid shifting market dynamics.

Click here to see the full list of 188 stocks from our Asian High Growth Tech and AI Stocks screener.

Let’s explore several standout options from the results in the screener.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog APIs and injections in China with a market capitalization of CN¥37.75 billion.

Operations: Gan & Lee Pharmaceuticals generates revenue primarily through the development, production, and sale of insulin and related products, amounting to approximately CN¥3.85 billion. The company’s focus on insulin analog APIs and injections positions it within China’s biopharmaceutical sector.

Gan & Lee Pharmaceuticals, a frontrunner in the insulin market, has shown robust financial and operational progress. In the recent quarter ending September 2025, the company reported a significant revenue increase to CNY 3.05 billion from CNY 2.25 billion year-over-year, with net income surging to CNY 818.34 million from CNY 507.27 million. These figures underscore a dynamic growth trajectory with earnings up by an impressive 59.4% over the past year, outpacing the broader biotech industry’s decline of -8.2%. Moreover, Gan & Lee’s strategic expansion into European markets is evidenced by their recent product approval by EMA’s CHMP for their biosimilar insulin glargine injection Ondibta®, marking it as the first Chinese-developed insulin product of its kind to enter this market after rigorous Phase III trials in Europe and the U.S., demonstrating therapeutic biosimilarity in efficacy and safety compared to established brands like Lantus®?. This move not only diversifies their portfolio but also enhances their global footprint—an essential step for sustained growth in a competitive sector.